Dr. William Rader - Breakthrough Cockayne Syndrome Treatment http://www.drwilliamrader.com - Breakthrough Stem Cell Treatment for Cockayne SyndromeFrom:William RaderViews:0 0ratingsTime:01:27More inScience Technology Read the original: Dr. William Rader - Breakthrough Cockayne Syndrome Treatment - Video … Continue reading →

La Jolla's annual meeting about stem cells was once about stem cell science in San Diego, largely presented and attended by stem cell scientists in San Diego. But the Stem Cell Meeting on the Mesa has grown to take on a national, or even international, flavor. Along with the growing emphasis on commercializing regenerative medicine research, companies in the field are hunting for corporate partners. And to reach the right people, they're willing to travel far. Of 35 companies and institutes presenting their technology Monday and Tuesday at the Sanford Consortium for Regenerative Medicine, just five are headquartered in San Diego County; 10 are headquartered elsewhere in California and 18 are from other states, along with one from the United Kingdom and one from the Netherlands. Other companies have sent representatives to scout partnering opportunities. The Stem Cell Meeting on the Mesa provides a focus on regenerative medicine hard to get in other conferences, said Alexander Vos, chief executive of PharmaCell, based in Maastricht, Netherlands. The company provides contract human cell and tissue culturing services. "It makes (discussions) much more effective," Vos said. "There are clearly other conferences as well, for instance the larger BIO (Biotechnology Industry Organization) meeting, but … Continue reading →

Gov. Rick Perry pushed Friday for Texas to become the center of adult stem-cell therapy, disregarding the federal government's increasing crackdown on clinics marketing the experimental medicine. Perry told a crowd of stem-cell researchers, industry leaders and patients gathered in Houston that the young science "holds the promise of miracles" desperately needed by people across the world and suggested Texas' "wildcat spirit" and "conducive climate" can make it happen here. "I'm not shy about asking people to relocate or start up their companies in Texas," said Perry, likening stem-cell treatment to previous innovations in space and heart care. "All of you outside the state of Texas - come on in. The water's fine. We've got an amazing environment here." Perry, who famously got the unlicensed treatment for an ailing back in 2011, said the state has made sure that innovators won't be "hindered by exorbitant taxes, wrapped up by bureaucratic red tape or at the mercy of predatory attorneys, seeking to make steady money off extensive, drawn-out court cases." Perry's remarks, made at the first of a planned annual Houston conference, came as the state appears headed toward a collision with the Food and Drug Administration, which has begun stepping … Continue reading →

ScienceDaily (Nov. 1, 2012) Tendon injuries affect athletic horses at all levels. Researchers from the University of Connecticut are studying the use of stem cells in treating equine tendon injuries. Their findings were published Oct. 16 in the Journal of Animal Science Papers in Press. Tendon injuries in horses tend to worsen over time as damage to the tendon creates lesions. Currently, horse owners treat tendon injuries by resting the horse and then carefully exercising the horse to control the growth of scar tissue in the tendon. Unfortunately, this treatment does not always work. "These injuries result in lameness, which requires substantial recovery time and carry a high risk of re-injury," write authors S.A. Reed and E.R. Leahy. Stem cells injections are already common veterinary medicine, and scientists are curious how to make stem cell treatments more effective. In this paper, the authors looked at the use of three types of stem cells: bone marrow-derived mesenchymal stem cells, adipose-derived stem cells and umbilical cord blood-derived stem cells. These types of cells have the potential to strengthen a tendon after injury. Implants of bone marrow-derived mesenchymal stem cells (BMSC) can increase collagen production and organized collagen fibers in the tendon. Adipose-derived … Continue reading →

Public release date: 1-Nov-2012 [ | E-mail | Share ] Contact: Rachel Mosey rmosey@mcw.edu Medical College of Wisconsin The Medical College of Wisconsin (MCW) Center for International Blood and Marrow Transplant Research (CIBMTR) successfully competed for, and was awarded, renewal of the Stem Cell Therapeutics Outcomes Database contract with the U.S. Health Resources and Services Administration (HRSA). The CIBMTR administers the database as a key component of the national hematopoietic cell transplantation program. Hematopoietic stem cells are the cells responsible for continual regeneration of circulating blood cells throughout life; they are not embryonic stem cells. The HRSA first awarded the contract to CIBMTR in 2006 to develop and maintain the national Stem Cell Therapeutic Outcomes Database (SCTOD), which is a standardized outcomes registry of allogeneic (related and unrelated donor cells) marrow and cord blood transplants performed in the United States. Funding for the first year of this new contract is $3.8 million, with an additional four years of negotiable funding. The outcomes registry of the CIBMTR currently contains the status of 330,000 transplant recipients, as well as critical information to continually evaluate the operations of the national transplant program. All U.S. transplant centers that perform allogeneic marrow and cord blood … Continue reading →

MANILA, Philippines Its supposed to cure various illnesses such as cancer, spinal cord injury and Parkinsons disease. Is stem cell therapy the cure-all that it is touted to be? Health Undersecretary Teodoro Herbosa said it is important to note that stem cell treatments are still at the experimental stage. "The advisory is very clear. This is still an investigative form of therapy. Anecdotal reports are not enough evidence to say there is treatment, he said in an interview on ANC's Talkback with Tina Palma. He said there are only two standard stem cell therapies considered effective and acceptable to the medical community. "To date, I can only name two cases that are considered standard therapy. That is bone marrow transplantation--one for severe cancer, blood cancer and the other one is bone marrow transplantation after chemotherapy for any type of cancer, he said. Herbosa said the Department of Health cannot confirm yet if stem cell treatment is indeed effective against certain diseases. Dr. Tranquilino Elicao Jr., an oncologist who availed of the treatment in April in Frankfurt, Germany, said stem cell therapy cured his high blood pressure, sugar, cholesterol and uric acid. He had 12 injections of cells, which came from … Continue reading →

By all preliminary accounts, the first stem-cell therapy treatment done on a canine in Nicholasville is a complete success. The 8-year-old golden Labrador and service dog, Booster, had been showing signs of hip dysplasia and became the first to undergo the revolutionary new stem-cell therapy in the recently completed animal clinic of MediVet America located off U.S. 27 and Moore Drive. Booster travels all over the world with owner Davis Hawn to teach others about the healing power of dogs, Hawn said. As Booster got older, Hawn noticed the dogs hips were hurting more as Booster showed pain just trying to sit down and began to have difficulty jumping into the truck. This prompted Hawn to look into methods of protecting and helping his best friend. He did not want Booster to suffer through the long and painful process of a hip replacement, and this is when he heard about the regenerative benefits of stem-cell therapy and the work MediVet was conducting. It just so happened to work out that the pair would be in Cincinnati last week, coinciding with the opening of the new Nicholasville clinic at MediVet by Joseph G. Yocum, D.V.M., who specializes in large-animal vet research. … Continue reading →

Courtesy of highlands.edu The diagnosis of a neurological disease can represent what many patients see as a point of no return, but research published on Thursday, Oct. 25 by UR scientists on stem cell therapy points toward a potential for lessening the severity of the outcomes of these diagnoses. The research, which was published in the journal Science, was conducted by UR researchers Steve Goldman, Maiken Nedergaard and Martha Windrem, addresses stem cells capable of transforming into the brains two main support cells, astrocytes and oligodendrocytes. The latter is lost in a family of neurological diseases classified as myelin disorders. Myelin disorders include Multiple Sclerosis, Cerebral Palsy and Tay-Sachs disease, among others. These diseases are well known for being life-altering, so research with implications for dampening their effects will have an important impact on patients and their families once brought to the practical level. This particular type of cell therapy would rely on programming stem cells to propagate glial progenitor cells. Progenitor cells then give rise to oligodendrocytes, which insulate neurons with a fatty substance called myelin. In total, this process ensures the speed and efficiency of neuronal communication. Without myelin, nerve communication throughout the body becomes weakened, which is … Continue reading →

NEW YORK, Nov. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer & autoimmune, skin and infectious diseases) http://www.reportlinker.com/p01022392/Autologous-Stem-Cell-and-Non-Stem-Cell-Based-Therapies-Market-2012-2017-Neurodegenerative-cardiovascular-cancer--autoimmune-skin-and-infectious-diseases.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy Autologous cell therapies are new therapeutic intervention where it introduces or uses cells or tissues from the individual, cultured, expanded and re-introduced at the site of the disease of the donor. They are widely promoted as next pillar or advancement in medical care. Growth of the market is very rapid especially in regulatory approvals, applications areas and rapid improvements in efficacy of treatment; it has enormous advantages over allogenic stem cell therapies. Autologous transplants are relatively safe procedures, with less rates of complications and infections compared with allogenic transplants. In many instances, much of the procedure can be done on an outpatient basis. It helps in treating various dreadful diseases by transplanting their own body cells where it results in meager chances of transplant rejection. We have also profiled leading players of this industry with their recent developments and other strategic industry activities. These include: Neostem (U.S.), Tengion (U.S.), Brainstorm Cell Therapeutics (U.S.), Dendreon Corporation (U.S.), Georgia Health Sciences University … Continue reading →

Under fire from the Food and Drug Administration, the Houston-area company that facilitated Gov. Rick Perry's controversial 2011 stem-cell treatment has stopped providing doctors with the cells patients banked at its facility for the procedure. In a response to an FDA warning that it is acting illegally by marketing the unlicensed therapy, Celltex Therapeutics Corp. wrote the federal agency this week that it has ceased enrolling patients in the clinical trials the state requires of stem-cell providers. Celltex was the Houston area's primary sponsor of such for-profit trials. "We're telling potential patients that we will still bank their stem cells and will enroll them in trials once new investigational drug applications have been submitted and reviewed by the FDA," said Amdrea Ferrenz, Celltex's executive vice president and legal counsel. "We hope that will be in a matter of months." Ferrenz called the FDA warning letter, publicly posted Tuesday, "a disappointment" but said it actually just moves up Celltex's plan to move into agency-approved trials targeting specific disease conditions. The Sugar Land company had been operating for nearly 18 months facilitating adult stem-cell procedures with little regulation. The Texas Medical Board in July began requiring that any stem-cell procedure be reviewed … Continue reading →